Last reviewed · How we verify

Prochlorperazine 10mg

Albert Einstein Healthcare Network · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Prochlorperazine 10mg is a Small molecule drug developed by Albert Einstein Healthcare Network. It is currently FDA-approved. Also known as: Compazine.

Prochlorperazine 10mg is a small molecule that acts as a dopamine D2 receptor antagonist. It is used to treat conditions such as migraine, nausea and vomiting, peripheral vertigo, and headache.

At a glance

Generic nameProchlorperazine 10mg
Also known asCompazine
SponsorAlbert Einstein Healthcare Network
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prochlorperazine 10mg

What is Prochlorperazine 10mg?

Prochlorperazine 10mg is a Small molecule drug developed by Albert Einstein Healthcare Network.

Who makes Prochlorperazine 10mg?

Prochlorperazine 10mg is developed and marketed by Albert Einstein Healthcare Network (see full Albert Einstein Healthcare Network pipeline at /company/albert-einstein-healthcare-network).

Is Prochlorperazine 10mg also known as anything else?

Prochlorperazine 10mg is also known as Compazine.

What development phase is Prochlorperazine 10mg in?

Prochlorperazine 10mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing